CJC-1295 vs AOD-9604
Compare the research profiles of CJC-1295 and AOD-9604. Read the individual guides for evidence and limitations.
How to interpret this comparison
This page summarizes database profiles and has not yet received a study-by-study editorial review. These compounds are filed under different research categories, so a direct treatment comparison may not answer a meaningful clinical question. Use the linked guides and primary sources to evaluate a specific claim.
How to read peptide studiesCJC-1295
CJC-1295 (with or without DAC)
growth-hormone
Phase 2 Clinical Trials
not-approved
AOD-9604
AOD-9604 (Anti-Obesity Drug)
weight-loss
Phase 2 Clinical Trials (discontinued)
not-approved
Detailed Comparison
| Aspect | CJC-1295 | AOD-9604 |
|---|---|---|
| Overview | A growth hormone releasing hormone (GHRH) analog that stimulates GH release. Available with DAC (Drug Affinity Complex) for extended half-life or without for shorter action.... | A fragment of human growth hormone (amino acids 177-191) marketed specifically for fat burning without affecting blood sugar or causing GH-related side effects. Now banned from compounding by FDA.... |
| Research topics (not established benefits) |
|
|
| Side Effects |
|
|
| Mechanism | Mimics GHRH to stimulate the pituitary gland to produce and release growth hormone. The DAC version binds to albumin for prolonged effect.... | Mimics the fat-burning effects of growth hormone without affecting blood sugar or cell proliferation. Stimulates lipolysis (fat breakdown) and inhibit... |
Frequently Asked Questions
Does a comparison establish which treatment is better?
Only appropriately designed evidence for the same clinical question can support that conclusion. Database categories and mechanisms alone cannot rank treatments.
Does this page establish that these compounds can be combined?
No. This page does not assess interactions or the benefit and safety of combined use. Individual studies cannot establish the effects of a combination.